Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|June 8, 2026
Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxisConrad Weidt, Adela Maria Neagoie, Maral Saadati, et al.
Acta Haematologica|October 8, 2019
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular ManagementSusanne Saussele, Wilhelm Haverkamp, Fabian Lang, et al.
Annals of Hematology|July 29, 2024
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patientsStefanie Jilg, Juliana Schwaab, Katja Sockel, et al.
The Journal of Experimental Medicine|April 17, 2013
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2Jonas S Jutzi, Ruzhica Bogeska, Gorica Nikoloski, et al.
Leukemia|July 12, 2020
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot studyCarl C Crodel, Kathleen Jentsch-Ullrich, Steffen Koschmieder, et al.
Leukemia|February 25, 2025
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN)Kirsi Manz, Florian H Heidel, Steffen Koschmieder, et al.
Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.
Haematologica|February 4, 2021
Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trialVeronika Brixner, Gesine Bug, Petra Pohler, et al.
Annals of Hematology|December 23, 2022
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study groupSteffen Koschmieder, Susanne Isfort, Dominik Wolf, et al.
Blood|October 28, 2018
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammationSebastien Jacquelin, Jasmin Straube, Leanne Cooper, et al.
Pageof 4